California-based biopharmaceutical company Gilead Sciences has contributed to support HIV/AIDS Advocacy related program at the Museum this December.
Gilead’s portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. They are the manufacturer of TRUVADA, the pre-exposure prophylaxis (PrEP) drug used to help reduce the risk of HIV-1 infection.
This is Gilead’s second major gift to the Museum this year. Gilead has supported previous HIV/AIDS advocacy related programming, including The Screening Room, and Then and Now: 35 Years of HIV/AIDS, and was the first sponsor to pledge support for the Museum’s forthcoming Gender Transition exhibit.
